
Congress may command government agencies to vet tech startups looking for federal funding in the near future, according to a Wall Street Journal (WSJ) report Sunday (May 8).
The report said a Department of Defense study found that China is exploiting a popular program to fund innovation among smaller American businesses.
China is reportedly using “state-sponsored methods” to target companies with Pentagon funding through the Small Business Innovation Research (SBIR) program, which has tried to promote innovation through competitive government awards.
According to the report, there were several instances of program participants who “dissolved their American companies” and joined Chinese government talent programs, instead working for places that support the People’s Liberation Army, an armed wing of the Chinese Communist Party.
The WSJ wrote that there’s been instances of SBIR recipients taking venture capital funds from Chinese state-owned firms, and others where they worked with Chinese entities that “support the country’s defense industry.”
According to the report, there needs to be a review to make sure the SBIR program can identify entities of concern which need a bigger review.
Lawmakers are now reportedly looking into a five-year reauthorization of the SBIR, along with a related Small Business Technology Transfer program. Both are part of a “sweeping, bipartisan” legislative package going through Capitol Hill, which will try and boost the U.S.’s competitiveness against China and other places.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas